Molecular Partners AG (SWX:MOLN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 117.47M -6.0% |
| Revenue (ttm) | n/a |
| Net Income | -58.02M |
| EPS | -1.55 |
| Shares Out | 37.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 78,336 |
| Average Volume | 27,055 |
| Open | 3.100 |
| Previous Close | 3.140 |
| Day's Range | 2.660 - 3.100 |
| 52-Week Range | 2.680 - 3.960 |
| Beta | 0.74 |
| RSI | 33.53 |
| Earnings Date | Aug 25, 2026 |
About Molecular Partners AG
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (D... [Read more]
Financial Performance
Financial StatementsNews
Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech ...
Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences
ZURICH-SCHLIEREN, Switzerland and Concord, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-...
Molecular Partners publishes MP0317 clinical data in Nature Cancer
Molecular Partners (MOLN) announced the publication of Phase 1 clinical data in Nature Cancer demonstrating the potential of the tumor-localized CD40 agonist, MP0317, to modulate the tumor microenviro...
Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech...
Molecular Partners announces presentation of preclinical data at AACR
Molecular Partners (MOLN) announced the presentation of new preclinical data across three posters at the American Association for Cancer Research, AACR, Annual Meeting 2026. The first poster outlines ...
Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass, April 19, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom...
Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotec...
Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custo...
Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins' Amenability to Multiple Isotopes
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custo...
Molecular Partners to Hold Three Poster Presentations at AACR 2026
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custo...
Molecular Partners Reports Highlights and Financial Results for Full Year 2025
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Zurich-Schlieren, Switzerland and Concord, Mass., March 12, 2026 – Ad hoc announcement pursuant to Art. 53 LR Molec...
Molecular Partners enters Radio-DARPin therapeutics pact with Eckert & Ziegler
Molecular Partners (MOLN) announced it has entered into an agreement with Eckert & Ziegler to enable the development and manufacturing of Radio-DARPin therapeutics. Under the non-exclusive agreement, ...
Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-b...
Molecular Partners AG Transcript: Study update
MP0712, a DLL3-targeting radiotherapeutic, showed strong tumor uptake and favorable biodistribution in SCLC patients, with healthy organs remaining within safety limits. The phase I/II trial is open, with safety and early efficacy data expected in 2024, and plans for dose escalation and future expansion to other radionuclides and indications.
Molecular Partners presents first imaging, dosimetry data of MP0712
Molecular Partners (MOLN) announced the presentation of first patient imaging and dosimetry data of MP0712, its DLL3-targeted Radio-DARPin candidate co-developed with strategic partner Orano Med, at t...
Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech...
Molecular Partners initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Molecular Partners (MOLN) with a Buy rating and $13 price target The company is advancing a “diversified portfolio of agents” centered on the DARPin platform,
Molecular Partners AG Transcript: 44th Annual J.P. Morgan Healthcare Conference
The presentation highlighted renewed optimism in biotech, with a strategic focus on radiotherapy and the MP0712 program. Early clinical data show promising tumor targeting and safety, with key updates expected throughout the year.
Molecular Partners provided update on latest progress, 2026 milestones
Molecular Partners (MOLN) provided an update on its latest progress, developments plans and expected 2026 milestones, which it will present at the 44th Annual J.P. Morgan Healthcare Conference in San
Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-b...
Molecular Partners forms Scientific Advisory Board
Molecular Partners (MOLN) announced the formation of a Scientific Advisory Board for its radiopharmaceuticals, chaired by Prof. Ken Herrmann, Chair of the Department of Nuclear Medicine at University ...
Molecular Partners presents updated data from Phase 1/2a trial of MP0533
Molecular Partners (MOLN) has announced it will present updated data from a Phase 1/2a trial of the multispecific T-cell engager MP0533 in patients with acute myeloid leukemia, AML, in a
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech...
Molecular Partners AG Transcript: Study Update
MP0712, a DLL3-targeted alpha therapy, showed promising preclinical and first-in-human imaging results, supporting rapid advancement to a U.S. phase I trial in small cell lung cancer. The program leverages unique half-life engineering and aims for accelerated approval, with expansion to other indications planned.
Molecular Partners presents new MP0712 data
Molecular Partners (MOLN) announced the presentation of new data on MP0712, its Radio-DARPin targeting DLL3, at the Targeted Radiopharmaceuticals Summit Europe, highlighting first human images and sup...